New Constipation Drug Under Development

Callisto Pharmaceuticals has submitted an investigational new drug (IND) application to study a substance SP-304 (Guanilib) related to a hormone that helps control the function of the intestine. In non-clinical studies, SP-304 has been well tolerated by laboratory animals. If approval is granted, SP-304 will be one of only two drugs intended to treat chronic constipation and constipation-predominant IBS (IBS-C). As many as 26 million Americans suffer from this condition, and as many as one in six has IBS. Medical News Today, April 10, 2008
2008-04-17 13:48:12